Skip to main content

Advertisement

SpringerLink
Log in

Pharmaceutical care program for type 2 diabetes patients in Brazil: a randomised controlled trial

  • Research Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background Brazilians with type 2 diabetes require action to improve haemoglobin A1C levels considering the fact that approximately 73 % of them have poor glycaemic control. Evidence has shown the potential benefits of pharmaceutical care programs in type 2 diabetes patients. Objective To evaluate the effect of a pharmaceutical care program on blood glucose, blood pressure and lipid profile in hyperglycaemic patients undergoing drug treatment for type 2 diabetes. Setting Six primary care units of the Brazilian public health system, Ouro Preto, Brazil. Method An open, randomised, controlled clinical trial was conducted for 6 months. Subjects aged 18 years or older who were using oral antidiabetic medications and presenting haemoglobin A1C levels ≥7 % were randomly assigned to receive only usual health care or usual health care plus pharmaceutical intervention. Main outcome measure Haemoglobin A1C. Results A total of 129 subjects were enrolled, and 100 patients completed the study. Compared to the control group (n = 50), the intervention group (n = 50) showed a significant reduction of haemoglobin A1C (−0.6 vs 0.7 %, p = 0.001), fasting plasma glucose, total cholesterol, LDL cholesterol, triglycerides and systolic blood pressure and a significant increase in HDL cholesterol and the use of lipid-modifying agents and platelet aggregation inhibitors. Conclusions This study suggests that a pharmaceutical care program may provide important contributions to reduce haemoglobin A1C in type 2 diabetes patients. Moreover, the promotion of the rational use of drugs may be better achieved in a context of pharmaceutical care programs in Brazil.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4–14.

    Article  PubMed  CAS  Google Scholar 

  2. Malerbi DA, Franco LJ. Multicenter study of the prevalence of diabetes mellitus and impaired glucose tolerance in the urban Brazilian population aged 30–69 years. The Brazilian Cooperative Group on the Study of Diabetes Prevalence. Diabetes Care. 1992;15:1509–16.

    Article  PubMed  CAS  Google Scholar 

  3. Sociedade Brasileira de Diabetes (SBD). Diretrizes da Sociedade Brasileira de Diabetes. [cited 2012 18 Jul]; Available from: http://www.diabetes.org.br/attachments/diretrizes09_final.pdf.

  4. Brasil. Saúde Brasil 2009: uma análise da situação de saúde e da agenda nacional e internacional de prioridades em saúde. [cited 2012 18 Jul]; Available from: http://portal.saude.gov.br/portal/arquivos/pdf/29_11_10_saude_brasil_web.pdf.

  5. Mendes ABV, Fittipaldi JAS, Neves RCS, Chacra AR, Moreira ED. Prevalence and correlates of inadequate glycaemic control: results from a nationwide survey in 6,671 adults with diabetes in Brazil. Acta Diabetol. 2010;47:137–45.

    Article  PubMed  Google Scholar 

  6. World Health Organization. The role of the pharmacist in the health care system. Vancouver, Canada; 1997. [cited 2012 18 Jul]; Available from: www.opas.org.br/medicamentos/site/UploadArq/who-pharm-97-599.pdf.

  7. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47:533–43.

    PubMed  CAS  Google Scholar 

  8. Turnacilar M, Sancar M, Apikoglu-Rabus S, Hursitoglu M, Izzettin FV. Improvement of diabetes indices of care by a short pharmaceutical care program. Pharm World Sci. 2009;31:689–95.

    Article  PubMed  Google Scholar 

  9. Fornos AJ, Andrés NF, Andrés JC, Guerra MM, Egea B. A pharmacotherapy follow-up program in patients with type-2 diabetes in community pharmacies in Spain. Pharm World Sci. 2006;28:65–72.

    Article  PubMed  Google Scholar 

  10. Krass I, Armour CL, Mitchell B, Brillant M, Dienaar R, Hughes J, et al. The pharmacy diabetes care program: assessment of a community pharmacy diabetes service model in Australia. Diabet Med. 2007;24:677–83.

    Article  PubMed  CAS  Google Scholar 

  11. Clifford RM, Davis WA, Batty KT, Davis TM. Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care. 2005;28:771–6.

    Article  PubMed  Google Scholar 

  12. Correr CJ, Melchiors AC, Fernandes-Llimós F, Pontarolo R. Effects of a pharmacotherapy follow-up in community pharmacies on type 2 diabetes patients in Brazil. Int J Clin Pharm. 2011;33:273–80.

    Article  PubMed  CAS  Google Scholar 

  13. Neto PRO, Marusic S, Lyra-Júnior DP, Pilger D, Cruciol-Souza JM, Gaeti WP, et al. Effect of a 36-month pharmaceutical care program on coronary heart disease risk in elderly diabetic and hypertensive patients. J Pharm Pharmaceut Sci. 2011;14:249–63.

    Google Scholar 

  14. Borges AP, Guidoni CM, Ferreira LD, de Freitas O, Pereira LR. The pharmaceutical care of patients with type 2 diabetes mellitus. Pharm World Sci. 2010;32:730–6.

    Article  PubMed  Google Scholar 

  15. Al Mazroui NR, Kamal MM, Ghabash NM, Yacout TA, Kole PL, McElnay JC. Influence of pharmaceutical care on health outcomes in patients with type 2 diabetes mellitus. Br J Clin Pharmacol. 2009;67:547–57.

    Article  PubMed  CAS  Google Scholar 

  16. Correr CJ, Pontarolo R, Wiens A, Rossignoli P, Melchiors AC, Radominski R, et al. Economic evaluation of pharmacotherapeutic follow-up in type 2 diabetes mellitus patients in community pharmacies. Arq Bras Endocrinol Metab. 2009;53:825–33.

    Article  Google Scholar 

  17. Cid AS. Avaliação da efetividade da atenção farmacêutica no controle da hipertensão arterial. Dissertação (Mestrado em Ciências Farmacêuticas). Universidade Federal de Ouro Preto, Ouro Preto; 2008.

  18. World Health Organization. ATC/DDD Index 2010. [cited 2012 18 Jul]; Available from: http://www.whocc.no/atc_ddd_index/.

  19. Friedewald WT, Levi RI, Fredrickson DS. Estimation of the concentration of low density lipoproteins cholesterol in plasma without use of the ultracentrifuge. Clin Chem. 1972;18:499–502.

    PubMed  CAS  Google Scholar 

  20. American Diabetes Association. Standards of medical care in diabetes—2011. Diabetes Care. 2011;34(Suppl. 1):S11–61.

    Article  Google Scholar 

  21. Cipolle RJ, Strand LM, Morley PC. Pharmaceutical care practice: the clinician’s guide. 2nd ed. New York: McGraw-Hill; 2004.

  22. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12.

    Article  PubMed  CAS  Google Scholar 

  23. Fera T, Bluml BM, Ellis WM. Diabetes ten city challenge: final economic and clinical results. J Am Pharm Assoc. 2009;49(3):383–91.

    Article  Google Scholar 

  24. Ivama AM, Noblat L, De Castro MS, De Oliveira NVBV, Jaramillo NM, Rech N. Consenso Brasileiro de atenção farmacêutica. Brasília: PAHO/WHO; 2002.

    Google Scholar 

  25. Peduzzi M. Multiprofessional healthcare team: concept and typology. Rev Saúde Pública. 2001;35:103–9.

    Article  PubMed  CAS  Google Scholar 

  26. Grant RW, Buse JB, Meigs JB. Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care. 2005;28:337–42.

    Article  PubMed  Google Scholar 

  27. Zafar A, Davies M, Azhar A, Khunti K. Clinical inertia in management of T2DM. Prim Care Diabetes. 2010;4:203–7.

    Article  PubMed  Google Scholar 

  28. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med. 2001;135:825–34.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors would like to thank the teachers and students of Education Program for Health Work and the pharmacists who contributed to this research.

Funding

The study was supported by CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior) and Universidade Federal de Ouro Preto.

Conflicts of interest

The authors have no conflict of interest with regard to this study.

Author information

Authors and Affiliations

  1. Post-Graduate Program in Pharmaceutical Sciences, School of Pharmacy, Federal University of Ouro Preto, Ouro Preto, Brazil

    Aline Oliveira Magalhães Mourão

  2. Department of Pharmacy, School of Pharmacy, Federal University of Ouro Preto, Rua Costa Sena 171, Ouro Preto, MG, Centro 35400-000, Brazil

    Wandiclécia Rodrigues Ferreira, Andrea Grabe Guimarães & Lisiane Silveira Ev

  3. Department of Pharmaceutical Products, School of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil

    Maria Auxiliadora Parreiras Martins & Adriano Max Moreira Reis

  4. Department of Clinical Analysis, School of Pharmacy, Federal University of Ouro Preto, Ouro Preto, Brazil

    Maria Ruth Gaede Carrillo

Authors
  1. Aline Oliveira Magalhães Mourão
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wandiclécia Rodrigues Ferreira
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria Auxiliadora Parreiras Martins
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Adriano Max Moreira Reis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maria Ruth Gaede Carrillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Andrea Grabe Guimarães
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lisiane Silveira Ev
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lisiane Silveira Ev.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mourão, A.O.M., Ferreira, W.R., Martins, M.A.P. et al. Pharmaceutical care program for type 2 diabetes patients in Brazil: a randomised controlled trial. Int J Clin Pharm 35, 79–86 (2013). https://doi.org/10.1007/s11096-012-9710-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-012-9710-7

Keywords

Search

Navigation